SCHEMBL4239136

SCHEMBL4239136

C1CCN(CC2CCC[N]C2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 2/20 0.59
ADRA2C P18825 1/20 0.59
ACHE P22303 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.39
CASP1 P29466 1/20 0.37
CASP4 P49662 1/20 0.37
CASP5 P51878 1/20 0.37
HRH3 Q9Y5N1 3/20 0.33
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
RAB9A P51151 1/20 0.32
KMT2A Q03164 1/20 0.32
OPRM1 P35372 2/20 0.31
OPRL1 P41146 2/20 0.31
OPRD1 P41143 1/20 0.31
OPRK1 P41145 1/20 0.31
MAPT P10636 2/20 0.31
TP53 P04637 1/20 0.31
TRPC5 Q9UL62 1/20 0.31
CHRM2 P08172 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4184118 0.98 CHRM5 (0.56) CHRM5ADRA2CACHESMN1; SMN2CASP1
SCHEMBL4184117 0.98 CHRM5 (0.56) CHRM5ADRA2CACHESMN1; SMN2CASP1
SCHEMBL4172196 0.88 CHRM5 (0.52) CHRM5ADRA2CACHESMN1; SMN2CASP1
SCHEMBL4172195 0.88 CHRM5 (0.52) CHRM5ADRA2CACHESMN1; SMN2CASP1
SCHEMBL3554561 0.83 ALDH1A1 (0.40) CHRM5ADRA2CACHEHRH3MEN1
SCHEMBL3551161 0.81 ADRA2C (0.58) CHRM5ADRA2CACHESMN1; SMN2CASP1
SCHEMBL3557098 0.78 CHRM5 (0.54) CHRM5ADRA2CACHESMN1; SMN2CASP1
SCHEMBL41997 0.77 CHRM5 (0.67) CHRM5ADRA2CACHESMN1; SMN2CASP1
SCHEMBL20643257 0.75 CHRM5 (1.00) CHRM5ADRA2CACHESMN1; SMN2CASP1
SCHEMBL1515104 0.75 CHRM5 (1.00) CHRM5ADRA2CACHESMN1; SMN2CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054440-A1 Quinoline derivatives as neurokinin receptor antagonists CARLING WILLIAM ROBERT 2009-02-26 US disclosed
EP-1888530-A2 QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2008-02-20 EP disclosed
WO-2006120478-A2 QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2006-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054440-A1 Quinoline derivatives as neurokinin receptor antagonists TACR2, TACR3, NPY2R CHRM5 278/4885ADRA2C 105/4885ACHE 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.